A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
Status:
Terminated
Trial end date:
2019-10-01
Target enrollment:
Participant gender:
Summary
This study is a randomized, double-blind, post-chemotherapy, adjuvant phase III clinical
trial. The primary aim of this study is to determine the value of regorafenib in improving
disease-free survival (DFS). Patients with Stage III (IIIB or IIIC) colon cancer as defined
by the 7th Edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual are
randomized 1:1 to placebo or the experimental agent regorafenib following completion of at
least four months of standard adjuvant therapy (e.g., 5-fluorouracil, leucovorin, oxaliplatin
(FOLFOX) , capecitabine, oxaliplatin (CapeOx), and other).